Oncozenge AB
The answer first
Does Oncozenge beat the market?
No, Oncozenge has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 1% of Nordic stocks
- Quality32
- Value3
- Trend3
No. 189 of 195 in healthcare
Max for seven days
Follow Oncozenge with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Oncozenge
Your first answer is free, no account needed.
Do you own Oncozenge, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Oncozenge and a few more. Free, no card.
Super Stock+44.6%In short
- Oncozenge has fallen 49.0% over the past year, including dividends.
- Overall, Oncozenge ranks better than 1% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 82.7%. The price is 79.7% below its peak now.
What do analysts think of Oncozenge?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 1% of Nordic stocks.
No. 189 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 155 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.48
- Asset turnoverSales divided by everything the company owns0.17
- Return on equityProfit divided by equity−170.8%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 178 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity4.7
- P/SPrice divided by sales15.2
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 184 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−51.5%
- 6 months−60.4%
- 9 months−48.9%
- 12 months−49.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Oncozenge
One fund we follow owns Oncozenge. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Oncozenge
Oncozenge AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1 employees.
OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.


See the full analysis of Oncozenge.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card